---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-014059"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:32:08.483998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences FY2022 net product sales $16.8M (+104% YoY); net loss $(78.0M)

## Summary
- Net product sales doubled to $16.8M in 2022 from $8.2M in 2021, driven by unit growth and promotional strategies.
- Total operating expenses cut 42% to $101.0M, exceeding the stated $50M cost reduction goal.
- Net loss attributable to common stockholders improved to $(78.0)M ($1.34/diluted share) from $(206.2)M ($23.63/share) in 2021.
- Cash at Dec 31, 2022: $2.8M unrestricted; raised $1.8M from senior secured convertible notes in Q1 2023.
- Appointed Ivy Zhang as CFO and Secretary effective April 13, 2023; targeting EBITDA break-even by year-end 2023.

## SEC filing metadata
- accession: 0001493152-23-014059
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/0001493152-23-014059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-014059
- JSON: https://secwatch.observer/filing/0001493152-23-014059.json
- Plain text: https://secwatch.observer/filing/0001493152-23-014059.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $16.8 million, net income $(78.0) million, or $(1.34) per share, EPS $(1.34) per share.
  - Period: the year ended December 31, 2022
  - Revenue: $16.8 million
  - Net income: $(78.0) million, or $(1.34) per share
  - EPS: $(1.34) per share
  - Result: reported results
  source text: citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. Highlights include: ● Increased Phexxi net product sales 104% to $16.8 million in 2022. ● Gained Phexxi coverage for more than 22.1 million new lives since January 1, 2023. ● More than 80% of Phexxi claims are now being approved (as of February 2023, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223014059/0001493152-23-014059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.